Ovid Therapeutics Inc. (OVID) stock
OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.26+0.04 (+1.80%)
Close on Nov 18, 2026Market cap $441.37MP/E –Yield –
Ovid Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Ovid Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $1.58M, down 76.2% year over year. For fiscal 2025 it was $7.25M, up 1181.3% from the year before. The highest annual figure on record is $208.38M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.25M | +1181.3% |
| FY2024 | Dec 31, 2024 | $566.00K | +44.4% |
| FY2023 | Dec 31, 2023 | $392.00K | -73.9% |
| FY2022 | Dec 31, 2022 | $1.50M | -99.3% |
| FY2021 | Dec 31, 2021 | $208.38M | +1551.6% |
| FY2020 | Dec 31, 2020 | $12.62M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $733.00K | -88.3% |
| Q1 FY2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $718.00K | +844.7% |
| Q3 FY2025 | Sep 30, 2025 | $132.00K | -23.7% |
| Q2 FY2025 | Jun 30, 2025 | $6.27M | +3611.2% |
| Q1 FY2025 | Mar 31, 2025 | $130.00K | -12.2% |
| Q4 FY2024 | Dec 31, 2024 | $76.00K | -46.5% |
| Q3 FY2024 | Sep 30, 2024 | $173.00K | +58.7% |
| Q2 FY2024 | Jun 30, 2024 | $169.00K | +125.3% |
| Q1 FY2024 | Mar 31, 2024 | $148.00K | +124.2% |
| Q4 FY2023 | Dec 31, 2023 | $142.00K | +206.8% |
| Q3 FY2023 | Sep 30, 2023 | $109.00K | +881.8% |
| Q2 FY2023 | Jun 30, 2023 | $75.00K | – |
| Q1 FY2023 | Mar 31, 2023 | $66.00K | -95.4% |
| Q4 FY2022 | Dec 31, 2022 | $46.28K | – |
| Q3 FY2022 | Sep 30, 2022 | $11.10K | – |
| Q2 FY2022 | Jun 30, 2022 | $0 | – |
| Q1 FY2022 | Mar 31, 2022 | $1.45M | -99.3% |
| Q4 FY2021 | Dec 31, 2021 | $0 | -100.0% |
| Q3 FY2021 | Sep 30, 2021 | $0 | -100.0% |
| Q2 FY2021 | Jun 30, 2021 | $0 | – |
| Q1 FY2021 | Mar 31, 2021 | $208.38M | – |
| Q4 FY2020 | Dec 31, 2020 | $5.70M | – |
| Q3 FY2020 | Sep 30, 2020 | $6.91M | – |
See a number that looks wrong?